AIFM1
protein-codingapoptosis inducing factor mitochondria associated 1
Gene summary
This gene encodes a flavoprotein essential for nuclear disassembly in apoptotic cells, and it is found in the mitochondrial intermembrane space in healthy cells. Induction of apoptosis results in the translocation of this protein to the nucleus where it affects chromosome condensation and fragmentation. In addition, this gene product induces mitochondria to release the apoptogenic proteins cytochrome c and caspase-9. Mutations in this gene cause combined oxidative phosphorylation deficiency 6 (COXPD6), a severe mitochondrial encephalomyopathy, as well as Cowchock syndrome, also known as X-linked recessive Charcot-Marie-Tooth disease-4 (CMTX-4), a disorder resulting in neuropathy, and axonal and motor-sensory defects with deafness and cognitive disability. Alternative splicing results in multiple transcript variants. A related pseudogene has been identified on chromosome 10. [provided by RefSeq, Aug 2015]
- PDCD8
- NAMSD
- AUNX1
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~41.2 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: XL
Disease ID:MONDO:0010689
Submitter: PanelApp Australia
Inheritance Pattern: XL
Disease ID:MONDO:0010378
Submitter: ClinGen
AIFM1was first reported in relation to X-linked hereditary sensory and autonomic neuropathy with deafness in 2006 (Wang et al., PMID:16816020). Using case-level data, this gene has been associated with X-linked disease that presents with a spectrum of auditory and sensory neuropathy phenotypes using the ClinGen Clinical Validity Framework. At least 24 variants (missense, splice site, in-frame deletion) that have been reported in 36 probands in 10 publications (PMIDs:25986071, 20362274, 23217327, 28888069, 28975462, 28842795, 27102849, 38456936, 36479253, 31523922) are included in this curation. Variants in this gene segregated with disease in >25 additional family members. This gene-disease association is also supported by functional assays, expression studies, and a mouse model (PMIDs: 23217327, 20362274, 25986071, 38449065) showing that AIFM1 plays a role in apoptosis and impairment of the auditory pathway in patients. In summary, AIFM1 is definitively associated with X-linked hereditary sensory and autonomic neuropathy with deafness. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was originally approved by the ClinGen Hearing Loss Working Group on 7/9/2018. It was reevaluated on 8/26/2025 (SOP Version 11). As a result of this reevaluation, the classification did not change.
Inheritance Pattern: XL
Disease ID:MONDO:0010437
Submitter: PanelApp Australia
Inheritance Pattern: XL
Disease ID:MONDO:0010275
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: XL
Disease ID:MONDO:0010437
Submitter: G2P
Inheritance Pattern: XL
Disease ID:MONDO:0010689
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: XL
Disease ID:MONDO:0010275
Submitter: PanelApp Australia
Inheritance Pattern: XL
Disease ID:MONDO:0009723
Submitter: ClinGen
The relationship between AIFM1 and Leigh syndrome spectrum was evaluated using the ClinGen Clinical Validity Framework as of August 17, 2020. The AIFM1 gene encodes apoptosis-inducing factor, mitochondria-associated, 1 which is an FAD-dependent oxidoreductase with important roles in oxidative phosphorylation, apoptosis, and redox control. The AIFM1 gene was first reported in relation to X-linked Leigh syndrome spectrum in 2010 (PMID: 20362274). Evidence supporting this gene-disease relationship includes case-level data and experimental data. This curation included four unique variants identified in four cases from four publications (PMIDs: 20362274, 22019070, 25934856, 28299359). No segregation data were available. AIFM1 variants have also been reported to be associated with X-linked Charcot-Marie-Tooth disease-4 (CMTX-4, also known as Cowchock syndrome). Loss of function is implicated as the mechanism of disease. This gene-disease association is also supported by expression, functional alteration in patient cells, functional alteration in non-patient cells, and animal models (PMIDs: 18791645, 20362274, 15526035, 29780003, 29531799, 18309327). In summary, there is moderate evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the NICHD U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on August 17, 2020 (SOP Version 7).
Inheritance Pattern: XL
Disease ID:MONDO:0010378
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: XL
Disease ID:MONDO:0010689
Submitter: Orphanet
Inheritance Pattern: XL
Disease ID:MONDO:0010378
Submitter: Orphanet
Inheritance Pattern: XL
Disease ID:MONDO:0010437
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: XL
Disease ID:MONDO:0010275
Submitter: Orphanet
Inheritance Pattern: XL
Disease ID:MONDO:0010437
Submitter: Orphanet
Inheritance Pattern: XL
Disease ID:MONDO:0010378
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Audiologic/Otolaryngologic; Biochemical; Cardiovascular; Musculoskeletal; Neurologic
Intervention: Audiologic/Otolaryngologic
Rationale: Early recognition and treatment of hearing impairment may improve outcomes, including speech and language development
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to AIFM1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_004208.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 43 | 101 | 5 | 149 | ||
| missense | 8 | 45 | 285 | 39 | 2 | 379 |
| nonsense | 7 | 7 | ||||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 46 | 46 | ||||
| Total | 8 | 45 | 381 | 140 | 7 | 581 |
Highest pathogenic variant AF is 0.000006374061
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_004199.1 | 16 | MANE Select | |
| Ensembl | ENSP00000287295.3 | 16 | MANE Select | |
| RefSeq | NP_001124318.2 | 7 | Standard | |
| RefSeq | NP_001124319.1 | 10 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Necroptosis - Homo sapiens (human)
- Apoptosis - Homo sapiens (human)
- Apoptosis Modulation and Signaling
- Nanomaterial induced apoptosis
- Apoptosis Modulation by HSP70
Biological Process
- response to ischemia
- apoptotic process
- activation of cysteine-type endopeptidase activity involved in apoptotic process
- chromosome condensation
- positive regulation of apoptotic process
Molecular Function
- DNA binding
- protein binding
- NAD(P)H oxidase activity
- oxidoreductase activity, acting on NAD(P)H
- protein dimerization activity
Cellular Component
- nucleus
- mitochondrion
- mitochondrial inner membrane
- mitochondrial intermembrane space
- cytosol
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000287295
- Coding exons
- 16
- Length
- 36525
- Individuals with no LoFs
- 125711
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 2
- Defined
- 125713
- p
- 0.00000795
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.49 | 130 | 238 | 0.545 | 0.0000184 | 3955 |
| Missense (PolyPhen) | 14 | 67.99 | 0.20591 | 1088 | ||
| Synonymous | 0.569 | 86 | 93.0 | 0.925 | 0.00000774 | 1231 |
| Loss of Function | 4.45 | 2 | 26.9 | 0.0743 | 0.00000222 | 408 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000012 | 0.0000088 | rare |
| South Asian | 0.000052 | 0.000033 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Functions both as NADH oxidoreductase and as regulator of apoptosis. In response to apoptotic stimuli, it is released from the mitochondrion intermembrane space into the cytosol and to the nucleus, where it functions as a proapoptotic factor in a caspase-independent pathway. In contrast, functions as an antiapoptotic factor in normal mitochondria via its NADH oxidoreductase activity. The soluble form (AIFsol) found in the nucleus induces 'parthanatos' i.e. caspase-independent fragmentation of chromosomal DNA. Interacts with EIF3G,and thereby inhibits the EIF3 machinery and protein synthesis, and activates casapse-7 to amplify apoptosis. Plays a critical role in caspase- independent, pyknotic cell death in hydrogen peroxide-exposed cells. Binds to DNA in a sequence-independent manner. {ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225, ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.;
- Disease
- DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6) [MIM:300816]: A mitochondrial disease resulting in a neurodegenerative disorder characterized by psychomotor delay, hypotonia, areflexia, muscle weakness and wasting. Some patients manifest prenatal ventriculomegaly and severe postnatal encephalomyopathy. {ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:22019070}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linked recessive neuromuscular disorder characterized by early childhood onset of a slowly progressive axonal sensorimotor neuropathy associated in some patients with sensorineural deafness and cognitive impairment. {ECO:0000269|PubMed:23217327}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form of hearing loss characterized by absent or severely abnormal auditory brainstem response, abnormal middle ear reflexes, abnormal speech discrimination, loss of outer hair cell function, and cochlear nerve hypoplasia. DFNX5 patients manifest auditory neuropathy with childhood onset, associated with distal sensory impairment affecting the peripheral nervous system. {ECO:0000269|PubMed:25986071}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.380
Intolerance Scores
- LoFtool
- 0.0837
- RVIS EVS
- -0.27
- RVIS percentile EVS
- 34.6
Essentials
- Essential (CRISPR)
- E
- Essential (CRISPR2)
- E
- Essential (gene trap)
- E
- Indispensability pred.
- E
- Indispensability score
- 0.773
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |